{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007497","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.514413+00:00","generated_at":"2026-05-21T16:49:22.736663+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MeiraGTx Q1 net loss $40.0M; announces $200M Hologen AI collaboration, RMAT for AAV-GAD","bullets":["Q1 net loss $40.0M ($0.51/share) vs $20.4M ($0.32) YoY; revenue $1.9M; cash $66.5M.","Hologen AI collaboration: $200M upfront to MeiraGTx; joint venture with $230M committed capital.","FDA granted RMAT designation for AAV-GAD Parkinson's; Phase 3 study planned H2 2025.","AAV-AIPL1 data in Lancet: 11/11 children with LCA4 responded; expedited approval discussions underway.","Bota-vec Phase 3 XLRP trial primary endpoint not met; secondary endpoints showed benefit across vision domains."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007497","json":"https://secwatch.observer/filing/0001558370-25-007497.json","markdown":"https://secwatch.observer/filing/0001558370-25-007497.md","text":"https://secwatch.observer/filing/0001558370-25-007497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837025007497/0001558370-25-007497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837025007497/mgtx-20250513x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:49:22.736663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}